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LETTER TO THE EDITOR
XPO1 expression worsens the prognosis 
of unfavorable DLBCL that can be effectively 
targeted by selinexor in the absence of mutant 
p53
Manman Deng1,2†, Mingzhi Zhang3†, Zijun Y. Xu‑Monette2† , Lan V. Pham4†, Alexandar Tzankov5, Carlo Visco6, 
Xiaosheng Fang2, Govind Bhagat7, Feng Zhu2, Karen Dybkaer8, April Chiu9, Wayne Tam10, Youli Zu11, 
Eric D. Hsi12, William W. L. Choi13, Jooryung Huh14, Maurilio Ponzoni15, Andrés J. M. Ferreri16, Michael B. Møller16, 
Benjamin M. Parsons17, J. Han van Krieken18, Miguel A. Piris19, Jane N. Winter20, Fredrick Hagemeister21, 
Lapo Alinari22, Yong Li23, Michael Andreeff24, Bing Xu1,25* and Ken H. Young2,26* 
Abstract 
The XPO1 inhibitor selinexor was recently approved in relapsed/refractory DLBCL patients but only demonstrated 
modest anti‑DLBCL efficacy, prompting us to investigate the prognostic effect of XPO1 in DLBCL patients and the 
rational combination therapies in high‑risk DLBCL. High XPO1 expression  (XPO1high) showed significant adverse 
prognostic impact in 544 studied DLBCL patients, especially in those with BCL2 overexpression. Therapeutic study in 
30 DLBCL cell lines with various molecular and genetic background found robust cytotoxicity of selinexor, especially 
in cells with BCL2-rearranged (BCL2‑R+) DLBCL or high‑grade B‑cell lymphoma with MYC/BCL2 double‑hit (HGBCL‑DH). 
However, expression of mutant (Mut) p53 significantly reduced the cytotoxicity of selinexor in overall cell lines and 
the BCL2‑R and HGBCL‑DH subsets, consistent with the favorable impact of  XPO1high observed in Mut‑p53‑expressing 
patients. The therapeutic effect of selinexor in HGBCL‑DH cells was significantly enhanced when combined with a BET 
inhibitor INCB057643, overcoming the drug resistance in Mut‑p53‑expressing cells. Collectively, these data suggest 
that XPO1 worsens the survival of DLBCL patients with unfavorable prognostic factors such as BCL2 overexpression 
and double‑hit, in line with the higher efficacy of selinexor demonstrated in BCL2‑R+ DLBCL and HGBCL‑DH cell lines. 
Expression of Mut‑p53 confers resistance to selinexor treatment, which can be overcome by combined INCB057643 
treatment in HGBCL‑DH cells. This study provides insight into the XPO1 significance and selinexor efficacy in DLBCL, 
important for developing combination therapy for relapsed/refractory DLBCL and HGBCL‑DH.
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To the editor
XPO1 (exportin 1) is a well-characterized nuclear export 
protein responsible for the nuclear-cytoplasmic transport 
and cellular homeostasis of up to 220 cargoes, includ-
ing the tumor suppressors p53 and IκB [1, 2]. Abnor-
mal XPO1 expression correlates with worse prognoses 
in human malignancies. Targeting XPO1 is a promis-
ing therapeutic approach in cancer [1, 2]. The XPO1 
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inhibitor selinexor has received FDA approval recently to 
treat refractory/relapsed (R/R) diffuse large B-cell lym-
phoma (DLBCL) after at least 2 lines of systemic therapy, 
showing an overall response rate of 28% in the SADAL 
trial [3]. However, it remains largely unknown whether 
and how XPO1 interplays with other adverse predic-
tors in DLBCL, how to predict selinexor effectiveness, 
and what combination therapy is optimal in R/R DLBCL 
patients. Here, we evaluated the prognostic significance 
of XPO1 expression in 544 well-characterized DLBCL 
cases, and investigated the therapeutic effect of selinexor 
in 30 DLBCL cell lines with variable genetic background.
Patients and Methods for this study are detailed in 
Additional file 1. XPO1 expression was observed in 217 
of 544 (40%) DLBCL patients with a mean level of 24%. 
High level of XPO1 expression  (XPO1high; > 30%) pre-
dicted significantly poor progressive-free survival (PFS) 
and overall survival (OS) in DLBCL patients (Fig.  1a). 
DLBCL is classified into prognostic favorable germinal 
center B-cell-like (GCB) and unfavorable activated B-cell-
like (ABC) subtypes [4].  XPO1high significantly short-
ened the PFS/OS in ABC-DLBCL but not GCB-DLBCL 
(Additional file 1: Figure S1A–B).  XPO1high showed sig-
nificant association with p53 overexpression  (p53+) and 
dual  p53+MYChigh expression but not clinical features 
(Additional file 1: Table S1), unlike a previous study using 
a different scoring system for XPO1 expression in 131 
DLBCL patients [5].
Whether  XPO1high interacts with other adverse 
prognostic factors and whether XPO1 is a potential 
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Fig. 1 Impact of XPO1 expression on patient survival in DLBCL. a In the entire cohort, DLBCL patients with high level of XPO1 expression  (XPO1high) 
had significantly worse OS and PFS than those with low or negative XPO1 expression  (XPO1low). b  XPO1high remarkably worsened the OS/PFS 
of DLBCL patients with  BCL2high expression. c  XPO1high significantly worsened the OS/PFS of patients with dual  MYChighBCL2high expression, and 
showed a trend of unfavorable effect on OS in patients with dual MYC/BCL2 rearrangements (MYC‑R+BCL2‑R+, HGBCL‑DH). d In TP53‑mutated (Mut) 
DLBCL patients without Mut‑p53 overexpression,  XPO1high showed a trend of unfavorable prognostic effect on OS. e In Mut‑TP53 DLBCL patients 
with Mut‑p53 overexpression,  XPO1high showed favorable prognostic effect, which was not significant in overall patients but significant in the 
subset with low BCL2 expression. f Significantly differentially expressed genes between  XPO1high and  XPO1low patients with concurrent Mut‑TP53 
and  MYChigh
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therapeutic target in high-risk DLBCL patients were 
further examined.  XPO1high remarkably worsened 
the OS and PFS of DLBCL with  BCL2high or dual 
 MYChighBCL2high expression (Fig. 1b,c), which is known 
as double-expressor lymphoma with unfavorable prog-
nosis [6]. Trends of adverse impact were also observed 
on PFS in MYC-rearranged  (R+) patients (P = 0.097; 
Additional file  1: Figure S1C) and OS in patients with 
dual MYC-R+BCL2-R+ (Fig.  1c) with dismal prognosis, 
defined as high-grade B-cell lymphoma with MYC/BCL2 
double-hit (HGBCL-DH) [7]. In patients with TP53 
mutation (Mut-TP53) [8],  XPO1high showed opposite 
prognostic effects in patients with and without Mut-p53 
protein overexpression [9], suggesting the nuclear export 
may attenuate the oncogenic gain-of-function of Mut-
p53. In contrast to the negative impact of  XPO1high in 
Mut-TP53/p53-negative patients (Fig.  1d) and in TP53-
wild type (Wt-TP53) patients (Additional file  1: Figure 
S1D), a favorable effect was associated with  XPO1high in 
Mut-TP53/p53-positive patients, which was significant 
in the  BCL2low subset (Fig. 1e). Gene expression profiling 
[4] analysis identified a distinct gene expression signature 
for  XPO1high in patients with Mut-TP53 and  MYChigh 
(Fig. 1f ), including upregulation of SIRPA, which encodes 
SIRPα, a receptor for CD47 transmitting “do not eat me” 
signal in phagocytosis, and downregulation of several 
genes related to DNA repair, metabolism, splicing, or 
biosynthesis (Additional file 1: Table S2).
Next, selinexor was assessed in 30 DLBCL cell lines, 
which resulted in significantly reduced cell viability 
with varying IC50 values (Fig.  2a). ABC-DLBCL and 
GCB-DLBCL cells were similarly vulnerable to selinexor 
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Fig. 2 Therapeutic effect of selinexor alone or in combination with a BET inhibitor INCB057643 in DLBCL cellular models. a The effect of 72‑h 
selinexor exposure on cell viability of 30 DLBCL cell lines. Waterfall graph showed the specific IC50 value of selinexor for each cell line with either 
ABC or GCB subtype of DLBCL. b DLBCL cell lines with BCL2 rearrangement (BCL2‑R) or HGBCL‑DH were more sensitive to selinexor with a lower 
mean IC50 value compared with other cell lines. c The presence of mutant (Mut) p53 in DLBCL cells significantly reduced the cytotoxicity of 
selinexor, especially significant in HGBCL‑DH cell lines. Selinexor promoted more significant apoptosis in Wt‑TP53 HGBCL‑DH cells than in Mut‑TP53/
p53‑expressing HGBCL‑DH cells. d INCB057643 and selinexor were cooperative in reducing cell viability and inducing apoptosis in HGBCL‑DH cells 
with Wt‑TP53 or Mut‑TP53/p53+
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(Additional file  1: Figure S1E), consistent with results 
in the SADAL clinical trial [3]. Biomarkers signifi-
cantly associated with higher sensitivity (lower IC50) to 
selinexor cytotoxicity included BCL2-R and HGBCL-DH 
(Fig.  2b) but not MYC-R. In contrast, presence of Mut-
TP53/p53+ significantly reduced the anti-lymphoma effi-
cacy of selinexor, especially in HGBCL-DH cells (Fig. 2c; 
Additional file 1: Figure S1F).
Limited efficacy of selinexor in HGBCL with Mut-
TP53/p53+ calls for combination strategy. Previous stud-
ies showed the synergy between selinexor and venetoclax 
in DLBCL and double-hit lymphoma [10, 11]. However, 
in the SADAL trial [3], patients with  MYChigh (but not 
 BCL2high) expression had a lower overall response rate 
than those without. MYC expression can be inhibited by 
targeting the bromodomain and extra-terminal domain 
(BET) proteins [12]. We therefore combined selinexor 
with a novel BET inhibitor INCB057643. Synergistic 
effect was observed in DLBCL/HGBCL cells, especially 
in HGBCL-DH cells with Mut-TP53/p53+ (Fig. 2d), sup-
porting INCB057643/selinexor combination as a thera-
peutic option for HGBCL-DH patients.
In summary, this study demonstrates that  XPO1high is a 
valuable biomarker in DLBCL with unfavorable prognos-
tic factors, predictive of significantly poorer outcomes 
in ABC-DLBCL,  BCL2high DLBCL, and double-expres-
sor lymphoma but not Mut-p53-expressing DLBCL. 
Targeting XPO1 with selinexor is similarly effective in 
GCB-DLBCL and ABC-DLBCL cells, and remarkably 
effective in BCL2-R+ DLBCL and HGBCL cells with-
out Mut-TP53/p53-positivity. In DLBCL/HGBCL cells, 
Mut-TP53/p53-positive expression predicts resistance 
to selinexor. INCB057643 synergizes with selinexor in 
HGBCL-DH cells, overcoming resistance in Mut-TP53/
p53-positive HGBCL-DH. These findings warrant future 
investigation on the role of XPO1, selinexor, and com-
bined BET inhibition in R/R DLBCL and HGBCL-DH.
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